Inside the EMA: How to Accelerate Vaccine Rollout – Safely
Vaccine development for COVID-19 may have been rapid, but no one has scrimped on safety. Increased speed is the result of pooled resources, funds, and expertise.
Stephanie Sutton | | Longer Read
“In the EU we have the important task as the European Medicines Agency and the enormous responsibility of evaluating the candidate vaccines. This vital work is needed to guarantee that when vaccines are used in the EU, we are sure that they are safe, of high quality and effective, and that their benefits outweigh any potential risk. We want the people of Europe to understand this work, the pride we take in doing this, and the enormous number of experts we bring together to make this happen, so people in the EU can trust the process, feel confident, and feel protected.”
- Emer Cooke, EMA Executive Director; speaking at the EMA Public stakeholder meeting on the development and authorization of safe and effective COVID-19 vaccines in the EU.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine